Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Benitec Biopharma Inc
Healthcare
P/NCAV
0.64x
Ticker
BNTC
Exchange
NASDAQ
Country
United States
Close
6.86 $
Mkt Cap
9.5M $
EV
-10.9M $
NCAV Burn Rate
-84.9%
Current Ratio
3.62
Debt/Equity
0.0
EV/REV
-144.9x
EV/EBIT
0.6x
EV/FCF
0.6x
Dilution
-14.0% p.A
Total Net Income
-104.4M $
Cheapness
99.0%
Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The Company’s platform, DNA-directed RNA interference (ddRNAi), combines ribonucleic acid (RNA) interference with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. The Company is also engaged in developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The Company-s BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to permanently silence the expression of the disease-causing gene (to slow, or halt, the biological mechanisms underlying disease progression in OPMD) and to simultaneously replace the mutant gene with a wildtype gene (to drive restoration of function in diseased cells).

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average